Salim Syed
Stock Analyst at Mizuho
(2.32)
# 2,716
Out of 5,046 analysts
75
Total ratings
43.33%
Success rate
0.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $2.11 | +563.51% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $63.59 | +32.10% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $154.27 | +9.55% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $298.43 | -6.18% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $119.79 | -2.33% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $9.04 | +143.36% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $45.28 | +259.98% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $14.85 | +21.21% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $23.42 | +45.18% | 1 | Apr 9, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $99 | $63.99 | +54.71% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $62.64 | -15.39% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.68 | +1,150.00% | 5 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $168 → $36 | $31.05 | +15.94% | 1 | Nov 16, 2022 |
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $2.11
Upside: +563.51%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $63.59
Upside: +32.10%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $154.27
Upside: +9.55%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $298.43
Upside: -6.18%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $119.79
Upside: -2.33%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $9.04
Upside: +143.36%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $45.28
Upside: +259.98%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $14.85
Upside: +21.21%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $23.42
Upside: +45.18%
CRISPR Therapeutics AG
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $63.99
Upside: +54.71%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $62.64
Upside: -15.39%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.68
Upside: +1,150.00%
Nov 16, 2022
Maintains: Buy
Price Target: $168 → $36
Current: $31.05
Upside: +15.94%